Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-09-06
1998-10-13
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514397, 514400, A61K 31415
Patent
active
058212590
ABSTRACT:
The invention provides a method for preventing and alleviating the harmful biological effects of secretion of chemicals from mast cells in the organism of mammals which leads to clinical conditions namely allergy, asthma, arthritis, dermatitis, interstitial cystitis, inflammatory and irritable bowel disease, migraines, multiple sclerosis, scleroderma or systemic sclerosis, ulcerative disease of the gastro-intestinal tract and urticaria, among others. The method consists in administering to said mammals and especially to human beings an amount, effective against said conditions, of an H.sub.3 receptor agonist which has inhibitory activity of neurohormonal activation of mast cell secretion.
REFERENCES:
patent: 4447443 (1984-05-01), Goldenberg
patent: 4767778 (1988-08-01), Arrang
Chemical Abstracts AN 1989: 614796, Cohen et al (EP 307172) Sep. 7, 1988.
Arrang et al, Chem Abst. 113(3): 23542u, Jul. 16, 1990, "Preparation of .alpha..beta.-dimethyl histamine and stereoisomers as Selective histamuric H.sub.3 receptor agonists".
Oishi et al "Effects of histamine H.sub.3 agonist (R) .alpha. Methyl-histamine . . . " J. Neurochem. 52(5): 1388-92, 1989.
Mansfield "The role of antihistamine Therapy in . . . " J. Allergy Clin Immunol. 86: 673-6 (1990 Oct.) Abstract only.
LandOfFree
H.sub.3 -receptor agonists as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with H.sub.3 -receptor agonists as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and H.sub.3 -receptor agonists as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-313531